Abstract
The development of an Active Pharmaceutical Ingredient (API) is divided into several stages and lasts an average of twelve years. It was estimated that only 0.005% of the new molecules with therapeutic activity come to be tested in humans, and for commercialization this factor decreases drastically. Therefore, the search for new modifications involving APIs that are already in the market,…